Role of some serum biomarkers in the early detection of diabetic cardiomyopathy

To assess the role of serum biomarkers in early prediction of diabetic cardiomyopathy. The participants were three groups of Type 2 diabetes mellitus (DM) patients having diastolic dysfunction (DM-DD), systolic dysfunction (DM-SD) and normal echocardiography (DM-N) with two control groups: non-DM diastolic dysfunction patients (DD) and healthy controls. AGEs, TNF-α, IL-6, IGFBP-7, creatinine and insulin were assessed. TNF-α, AGEs, creatinine and insulin panel had area under the curve (AUC) of 0.913 in distinguishing DM-DD from DM-N (78.7% sensitivity and 100% specificity). IL-6 and AGEs panel had AUC 0.795 for differentiating DM-SD from DM-DD (90.6% sensitivity). IL-6, TNF-α and AGEs panel had AUC 0.924 for differentiating diabetic cardiomyopathy from DM-N (85% sensitivity and specificity). A panel of AGEs, IL-6, TNF-α, insulin and creatinine might be used for early detection of DM-DD among T2DM patients. Diabetic cardiomyopathy is a disorder of the heart muscle among diabetic people. The early stage of diabetic cardiomyopathy is reversible, while later stages progress to heart failure. We were able to identify a panel of serum biomarkers that can be used for detection of the reversible stage of diabetic cardiomyopathy with 90% sensitivity.